Goodpasture disease - Characterization of a single conformational epitope as the target of pathogenic autoantibodies

Citation
T. Hellmark et al., Goodpasture disease - Characterization of a single conformational epitope as the target of pathogenic autoantibodies, J BIOL CHEM, 274(36), 1999, pp. 25862-25868
Citations number
25
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF BIOLOGICAL CHEMISTRY
ISSN journal
00219258 → ACNP
Volume
274
Issue
36
Year of publication
1999
Pages
25862 - 25868
Database
ISI
SICI code
0021-9258(19990903)274:36<25862:GD-COA>2.0.ZU;2-A
Abstract
Goodpasture disease is a prototype autoimmune disease characterized by the formation of autoantibodies against the heterotrimeric basement membrane co llagen type IV, which causes a rapidly progressive glomerulonephritis, The pathogenic antibody response is directed to the non-collagenous (NC1) domai n of the alpha 3 chain of type IV collagen (alpha 3(IV)NC1), but not to the homologous region of the alpha 1(IV)NC1, To identify the conformation-depe ndent immunodominant epitope on the alpha 3(IV)NC1, a variety of recombinan t NC1 domains were constructed by replacing single residues of alpha 3(IV) with the corresponding amino acids from the nonreactive alpha 1(IV) chain. Replacement mutations were identified that completely destroyed the Goodpas ture epitope in the alpha 3(IV) chain. Based on the identification of these critical positions, the epitope was finally reconstructed within the frame of the alpha 1(IV) chain. The substitution of nine discontinuous positions in the alpha 1(IV)NC1 with amino acid residues from the alpha 3 chain resu lted in a recombinant construct that was recognized by all patients' sera ( n = 20) but by none of the sera from healthy controls (n = 10). This provid es, for the first time, the molecular characterization of a single immunodo minant conformational epitope recognized by pathogenic autoantibodies in a human autoimmune disease, representing the basis for the development of new epitope-specific strategies in the treatment of Goodpasture disease.